Surgery plus targeted therapy for advanced EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether removing the main lung tumor with surgery, combined with an EGFR-targeted pill, can help people with stage IV lung cancer that has a specific EGFR mutation. The goal is to improve outcomes compared with medication alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IV non-small cell lung cancer (NSCLC) that can be surgically removed.
- Your cancer must have a specific EGFR mutation — either an exon 19 deletion or an L858R mutation.
- You should be in good physical condition (able to care for yourself and carry on daily activities).
- You must be a candidate for surgery to remove the main tumor and at least one other site of cancer.
- You must be willing to have your tumor tested after surgery for genetic changes (next-generation sequencing).
- You should not have received prior treatment with an EGFR-targeted pill (unless you're still within your first 6 weeks of afatinib).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding surgery to remove the main lung tumor improves outcomes for people with stage 4 lung cancer that has a specific EGFR mutation and only limited spread. If you qualify, you will take the targeted drug osimertinib for 12 weeks, and if the tumor responds, you may be randomly assigned to either continue the drug alone or have the main tumor surgically removed and then continue the drug.
This trial tests whether removing the main lung tumor with surgery and then taking the targeted drug osimertinib helps people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this approach can improve outcomes compared to just taking the drug alone.
This trial tests whether a targeted therapy pill (EGFR-TKI) can control small spots in the other lung after surgery for early-stage lung cancer. It's for people whose cancer has a specific EGFR gene change and who still have suspicious spots in the opposite lung after one side is removed.
This trial tests giving targeted therapy pills before and after surgery for stage III lung cancer with certain rare gene changes. The goal is to see if this approach helps shrink or control the cancer better than surgery alone.
This trial tests two different treatment plans before lung cancer surgery. Both plans start with a targeted pill (limertinib), then one adds immunotherapy plus chemotherapy, and the other adds just chemotherapy. The goal is to see which combination helps shrink the tumor more before surgery.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.